Suvemcitug

苏维西塔单抗

Report date: 2026/05/15 20:01:45

Base Information

Drug NameSuvemcitug
Drug Alias Name重组抗VEGF人源化单克隆抗体Humanized anti-VEGF antibody (Epitomics)重组抗VEGF人源化单抗Recombinant Humanized Anti-VEGF Monoclonal Antibody (Epitomics)Sevacizumab +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsVascular endothelial growth factor A inhibitorsT lymphocytes stimulants +[4] 
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursWet age-related macular degenerationMacular Degeneration +[8] 
Global Approved IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Approved Indications in ChinaFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/06/30
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEpitomics IncApexigen Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu T-Mab Bio-Pharmaceuticals Co LtdJiangsu Xiansheng biopharmaceutical Co LtdJiangsu Xiansheng Medicament Research Co Ltd +[7] 
Inactive CompaniesShanghai Xiansheng Zaiming Pharmaceutical Biotechnology Co Ltd
Active IndicationsWet age-related macular degenerationFallopian Tube NeoplasmsOvarian Neoplasms +[6] 
Inactive IndicationsSolid tumoursMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A